Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Dr Anne Mortimer

Director of Planning (Enterprise & London)

T: 020 7679 4882
E: a.mortimer@ucl.ac.uk

Anne Mortimer

As Director of Planning (Enterprise & London), Anne is responsible for managing strategic projects, developing new enterprise policies, and developing and reporting metrics on behalf of the Vice-Provost.

Anne has a DPhil in synthetic organic chemistry and 10 years of research experience at the University of Oxford, University of Würzburg and in the Department of Chemistry at UCL.